Open Journal Systems

Recent advances in head and neck cancer: The beginning of the immunotherapy era in HNSCC

Mayur A. Gadhikar ()
Jeffrey N. Myers ()


After bringing unprecedented clinical benefits to patients with advanced melanoma, the field of immunotherapy has continued to break new ground and progressively transform the therapeutic landscape across many other cancers. The American Society of Clinical Oncology (ASCO), acknowledging the transformative impact and future potential of immunotherapy, has named it the “Advance of the Year” for the second consecutive year.


immunotherapy; head and neck squamous cell carcinoma; immune-checkpoint inhibitors

Full Text:



Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2017; 35(12):1341–1367. doi: 10.1200/JCO.2016.71.5292.

Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): Anti-tumor immunity and clinical applications. Ann Transl Med 2016; 4(9):173. doi: 10.21037/atm.2016.03.34.

Suh Y, Amelio I, Guerrero Urbano T, Tavassoli M. Clinical update on cancer: Molecular oncology of head and neck cancer. Cell Death Dis 2014; 5: e1018. doi: 10.1038/cddis.2013.548.

Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nature reviews Cancer 2011; 11(1): 9–22. doi: 10.1038/nrc2982.

Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371(9625): 1695–1709. doi: 10.1016/S0140-6736(08)60728-X.

Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92(1): 4–14. doi: 10.1016/j.radonc.2009.04.014.

Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute 2008; 100(4): 261–269. doi: 10.1093/jnci/djn011.

Brockstein BE. Management of recurrent head and neck cancer: Recent progress and future directions. Drugs 2011; 71(12): 1551–1559. doi: 10.2165/11592540-000000000-00000.

Szturz P, Vermorken JB. Immunotherapy in head and neck cancer: Aiming at EXTREME precision. BMC Med 2017; 15(1): 110. doi: 10.1186/s12916-017-0879-4.

Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) 2015; 7(4): 2397–2414. doi: 10.3390/cancers7040900.

Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015; 33(29): 3293–3304. doi: 10.1200/JCO.2015.61.1509.

Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8(8): 2553–2562.

Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8(10): 3137–3145.

Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 2013; 49(12): 1089–1096. doi: 10.1016/j.oraloncology.2013.09.009.

Allen C, Duffy S, Teknos T, Islam M, Chen Z, et al. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007; 13(11): 3182–3190. doi: 10.1158/1078-0432.CCR-06-3047.

Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy. Cancer Discov 2014; 4(5): 522–526. doi: 10.1158/2159-8290.CD-13-0985.

Fujii N, Shomori K, Shiomi T, Nakabayashi M, Takeda C, et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: Their clinicopathological and prognostic significance. J Oral Pathol Med 2012; 41(6): 444–451. doi: 10.1111/j.1600-0714.2012.01127.x.

Balermpas P, Rodel F, Liberz R, Oppermann J, Wagenblast J, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer 2014; 111(8): 1509–1518. doi: 10.1038/bjc.2014.446.

Economopoulou P, Kotsantis I, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: Combinatorial immunotherapy approaches. ESMO Open 2016; 1(6): e000122. doi: 10.1136/esmoopen-2016-000122.

Ferris R, Gillison ML. Nivolumab for Squamous-Cell Cancer of Head and Neck. N Engl J Med 2017; 376(6): 596. doi: 10.1056/NEJMc1615565.

Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375(19): 1856–1867. doi: 10.1056/NEJMoa1602252.

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17(7): 956–965. doi: 10.1016/S1470-2045(16)30066-3.

Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: Lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011; 132(3): 315–325. doi: 10.1111/j.1365-2567.2010.03398.x.

Schaer DA, Cohen AD, Wolchok JD. Anti-GITR antibodies--potential clinical applications for tumor immunotherapy. Curr Opin Investig Drugs 2010; 11(12): 1378–1386.

Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009; 229(1): 173–191. doi: 10.1111/j.1600-065X.2009.00766.x.

Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22(5): 633–642. doi: 10.1016/j.immuni.2005.03.013.



  • There are currently no refbacks.

Copyright (c) 2018 Mayur A. Gadhikar, Jeffrey N. Myers

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.